Composition for inducing proliferation or accumulation of regulatory T cells
US-9415079-B2 · Aug 16, 2016 · US
Composition for inducing proliferation or accumulation of regulatory T cells
US12214003B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12214003-B2 |
| Application number | US-202418676470-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 28, 2024 |
| Priority date | Jun 4, 2010 |
| Publication date | Feb 4, 2025 |
| Grant date | Feb 4, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising a spore-forming fraction of human fecal matter; wherein the pharmaceutical composition is formulated for oral administration; wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition has been obtained by enriching human fecal matter for a population of spore-forming bacteria therein and comprises two or more bacterial strains; and wherein the spore-forming fraction of human fecal matter in the pharmaceutical composition induces proliferation and/or accumulation of regulatory T cells and wherein the pharmaceutical composition is in the form of a capsule. 2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is configured to be administered after antibiotic treatment. 3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the intestine of a human. 4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the colon of a human. 5. The pharmaceutical composition of claim 1 , wherein the capsule comprises a hydrogel. 6. The pharmaceutical composition of claim 5 , wherein the hydrogel comprises a cellulose-based polymer. 7. The pharmaceutical composition of claim 1 , wherein the capsule comprises a pH-sensitive composition comprising one or more enteric polymers. 8. The pharmaceutical composition of claim 1 , wherein the regulatory T cells are Foxp3+ regulatory T cells. 9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition does not include bacteria belonging to the genus Bacteroides.
Assignees
Inventors
Classifications
Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title
Expression markers · CPC title
characterised by the type of response, e.g. Th1, Th2 · CPC title
from bacteria · CPC title
oral/gastrointestinal · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12214003B2 cover?
- It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium o…
- Who is the assignee on this patent?
- Univ Tokyo
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).